Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.

J Diabetes Res · 2018 · PMC5830021 · PMID 29619381

Europe PMC DOI

hedged sentence

0.0678

closest p · 1.4× alpha

0.0678

boldest claim

The sentences

a nonsignificant trendP = 0.0678so close (0.05 < p ≤ 0.1)

In the high-risk cohort, patients treated with Glar-300 showed a nonsignificant trend toward lower nocturnal hypoglycemia compared with those treated with Glar-100 [25.3% versus 38.0% ( P = 0.0678) for the EDITION 2 trial and 24.2% versus 32.7% ( P = 0.1903) for the EDITION 3 trial].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.